BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29339222)

  • 1. Measurement variability of liver metastases from neuroendocrine tumors on different magnetic resonance imaging sequences.
    Lestra T; Kanagaratnam L; Mulé S; Janvier A; Brixi H; Cadiot G; Dohan A; Hoeffel C
    Diagn Interv Imaging; 2018 Feb; 99(2):73-81. PubMed ID: 29339222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurements of Hepatic Metastasis on MR Imaging:: Assessment of Interobserver and Intersequence Variability.
    Karademir I; Ward E; Peng Y; Wise L; Buckle C; Kunnavakkam R; Oto A
    Acad Radiol; 2016 Feb; 23(2):132-43. PubMed ID: 26548855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is diffusion-weighted MRI sufficient for follow-up of neuroendocrine tumour liver metastases?
    Lavelle LP; O'Neill AC; McMahon CJ; Cantwell CP; Heffernan EJ; Malone DE; Daly L; Skehan SJ
    Clin Radiol; 2016 Sep; 71(9):863-8. PubMed ID: 27345612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Magnetic Resonance (MR) Biomarkers for Assessment of Response With Response Evaluation Criteria in Solid Tumors: Comparison of the Measurements of Neuroendocrine Tumor Liver Metastases (NETLM) With Various MR Sequences and at Multiple Phases of Contrast Administration.
    Luersen GF; Wei W; Tamm EP; Bhosale PR; Szklaruk J
    J Comput Assist Tomogr; 2016; 40(5):717-22. PubMed ID: 27636124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging.
    d'Assignies G; Fina P; Bruno O; Vullierme MP; Tubach F; Paradis V; Sauvanet A; Ruszniewski P; Vilgrain V
    Radiology; 2013 Aug; 268(2):390-9. PubMed ID: 23533288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are we reproducible in measurement of NET liver metastasis?
    Moalla S; Arfi Rouche J; Foulon S; Caramella C; Ternes N; Planchard D; Goere D; Ducreux M; Scoazec JY; Deschamps F; Dromain C; Baudin E
    Dig Liver Dis; 2017 Oct; 49(10):1121-1127. PubMed ID: 28844707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Phase of Dynamic Computed Tomography for Reliable Size Measurement of Metastatic Neuroendocrine Tumors of the Liver: Comparison between Pre- and Post-Contrast Phases.
    Huh J; Park J; Kim KW; Kim HJ; Lee JS; Lee JH; Jeong YK; Shinagare AB; Ramaiya NH
    Korean J Radiol; 2018; 19(6):1066-1076. PubMed ID: 30386138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR diagnosis of hepatic metastases from neuroendocrine tumors versus hemangiomas: relative merits of dynamic gadolinium chelate-enhanced gradient-recalled echo and unenhanced spin-echo images.
    Soyer P; Gueye C; Somveille E; Laissy JP; Scherrer A
    AJR Am J Roentgenol; 1995 Dec; 165(6):1407-13. PubMed ID: 7484575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases: Does Hepatobiliary Phase Imaging Improve Lesion Conspicuity and Interobserver Agreement of Lesion Measurements?
    Morse B; Jeong D; Thomas K; Diallo D; Strosberg JR
    Pancreas; 2017 Oct; 46(9):1219-1224. PubMed ID: 28902795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine liver metastases: Value of apparent diffusion coefficient and enhancement ratios for characterization of histopathologic grade.
    Besa C; Ward S; Cui Y; Jajamovich G; Kim M; Taouli B
    J Magn Reson Imaging; 2016 Dec; 44(6):1432-1441. PubMed ID: 27227756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial.
    Elf AK; Andersson M; Henrikson O; Jalnefjord O; Ljungberg M; Svensson J; Wängberg B; Johanson V
    World J Surg; 2018 Feb; 42(2):506-513. PubMed ID: 29167951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.
    Liapi E; Geschwind JF; Vossen JA; Buijs M; Georgiades CS; Bluemke DA; Kamel IR
    AJR Am J Roentgenol; 2008 Jan; 190(1):67-73. PubMed ID: 18094295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of MRI pulse sequences for prediction of size of hepatocellular carcinoma at explant evaluation.
    Seuss CR; Kim MJ; Triolo MJ; Hajdu CH; Rosenkrantz AB
    AJR Am J Roentgenol; 2014 Aug; 203(2):300-5. PubMed ID: 25055263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases.
    Torkzad MR; Riddell AM; Chau I; Cunningham D; Koh DM
    AJR Am J Roentgenol; 2021 Mar; 216(3):669-676. PubMed ID: 33502225
    [No Abstract]   [Full Text] [Related]  

  • 15. Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent.
    Tirumani SH; Jagannathan JP; Braschi-Amirfarzan M; Qin L; Balthazar P; Ramaiya NH; Shinagare AB
    Abdom Radiol (NY); 2018 Sep; 43(9):2329-2339. PubMed ID: 29470627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hepatic lesion types defined by T2-weighted and dynamic gadolinium-enhanced MR imaging in patients with metastasized neuroendocrine tumors.
    Milin S; Brunaud L; Orry X; Bastien C; Klein M; Bresler L; Laurent V
    Abdom Radiol (NY); 2016 Nov; 41(11):2132-2141. PubMed ID: 27315078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial?
    Kim YK; Kim CS; Han YM; Lee YH
    Clin Radiol; 2011 Jun; 66(6):489-96. PubMed ID: 21367403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroenteropancreatic neuroendocrine tumors: impact of consistent contrast agent selection on radiologists' confidence in hepatic lesion assessment on restaging MRIs.
    Balthazar P; Shinagare AB; Tirumani SH; Jagannathan JP; Ramaiya NH; Khorasani R
    Abdom Radiol (NY); 2018 Jun; 43(6):1386-1392. PubMed ID: 28840281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases.
    Piana G; Trinquart L; Meskine N; Barrau V; Beers BV; Vilgrain V
    J Hepatol; 2011 Jul; 55(1):126-32. PubMed ID: 21145857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI.
    Rockall AG; Planche K; Power N; Nowosinska E; Monson JP; Grossman AB; Reznek RH
    Neuroendocrinology; 2009; 89(3):288-95. PubMed ID: 19023191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.